BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 35095843)

  • 1. HPV-16 E7-Specific Cellular Immune Response in Women With Cervical Intraepithelial Lesion Contributes to Viral Clearance: A Cross-Sectional and Longitudinal Clinical Study.
    Zhang L; Shi X; Zhang Q; Mao Z; Shi X; Zhou J; Jian A; Zhu R; Jiang S; Lu W
    Front Immunol; 2021; 12():768144. PubMed ID: 35095843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surgery followed by persistence of high-grade squamous intraepithelial lesions is associated with the induction of a dysfunctional HPV16-specific T-cell response.
    de Vos van Steenwijk PJ; Piersma SJ; Welters MJ; van der Hulst JM; Fleuren G; Hellebrekers BW; Kenter GG; van der Burg SH
    Clin Cancer Res; 2008 Nov; 14(22):7188-95. PubMed ID: 19010835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell mediated immunity against HPV16 E2, E6 and E7 peptides in women with incident CIN and in constantly HPV-negative women followed-up for 10-years.
    Paaso A; Koskimaa HM; Welters MJ; Grénman S; Syrjänen K; van der Burg SH; Syrjänen S
    J Transl Med; 2015 May; 13():163. PubMed ID: 25990808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of human papillomavirus type 16-specific immunologic responses in a normal and an human papillomavirus-infected populations.
    Cheng WF; Lee CN; Su YN; Chang MC; Hsiao WC; Chen CA; Hsieh CY
    Immunology; 2005 May; 115(1):136-49. PubMed ID: 15819706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions.
    de Vos van Steenwijk PJ; Ramwadhdoebe TH; Löwik MJ; van der Minne CE; Berends-van der Meer DM; Fathers LM; Valentijn AR; Oostendorp J; Fleuren GJ; Hellebrekers BW; Welters MJ; van Poelgeest MI; Melief CJ; Kenter GG; van der Burg SH
    Cancer Immunol Immunother; 2012 Sep; 61(9):1485-92. PubMed ID: 22684521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of E6 and E7 levels in high-risk HPV16 type cervical lesions with CCL20 and Langerhans cells.
    Jiang B; Xue M
    Genet Mol Res; 2015 Sep; 14(3):10473-81. PubMed ID: 26400278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia.
    Kadish AS; Ho GY; Burk RD; Wang Y; Romney SL; Ledwidge R; Angeletti RH
    J Natl Cancer Inst; 1997 Sep; 89(17):1285-93. PubMed ID: 9293919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profiling of serum antibodies against human papillomavirus antigens in Korean women with cervical intraepithelial neoplasia and cervical cancer.
    Jin Y; Choi JW; Kim HJ; Eddouzi J; Kim SC; Ju W; Kim YH; Kim HJ
    Cancer Med; 2018 Nov; 7(11):5655-5664. PubMed ID: 30353680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-17 suppresses immune effector functions in human papillomavirus-associated epithelial hyperplasia.
    Gosmann C; Mattarollo SR; Bridge JA; Frazer IH; Blumenthal A
    J Immunol; 2014 Sep; 193(5):2248-57. PubMed ID: 25063870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deficiencies in myeloid antigen-presenting cells in women with cervical squamous intraepithelial lesions.
    Lee BN; Follen M; Rodriquez G; Shen DY; Malpica A; Shearer WT; Reuben JM
    Cancer; 2006 Sep; 107(5):999-1007. PubMed ID: 16874820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell response to human papillomavirus type 58 L1, E6, And E7 peptides in women with cleared infection, cervical intraepithelial neoplasia, or invasive cancer.
    Chan PK; Liu SJ; Cheung TH; Yeo W; Ngai SM; Cheung JL; Chong P; Man S
    Clin Vaccine Immunol; 2010 Sep; 17(9):1315-21. PubMed ID: 20668141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral vaccination against HPV E7 for treatment of cervical intraepithelial neoplasia grade 3 (CIN3) elicits E7-specific mucosal immunity in the cervix of CIN3 patients.
    Kawana K; Adachi K; Kojima S; Taguchi A; Tomio K; Yamashita A; Nishida H; Nagasaka K; Arimoto T; Yokoyama T; Wada-Hiraike O; Oda K; Sewaki T; Osuga Y; Fujii T
    Vaccine; 2014 Oct; 32(47):6233-9. PubMed ID: 25258102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel oligomannose liposome-DNA complex DNA vaccination efficiently evokes anti-HPV E6 and E7 CTL responses.
    Mizuuchi M; Hirohashi Y; Torigoe T; Kuroda T; Yasuda K; Shimizu Y; Saito T; Sato N
    Exp Mol Pathol; 2012 Feb; 92(1):185-90. PubMed ID: 22032938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inverse correlation of cellular immune responses specific to synthetic peptides from the E6 and E7 oncoproteins of HPV-16 with recurrence of cervical intraepithelial neoplasia in a cross-sectional study.
    Sarkar AK; Tortolero-Luna G; Follen M; Sastry KJ
    Gynecol Oncol; 2005 Dec; 99(3 Suppl 1):S251-61. PubMed ID: 16188303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-mediated immune response to human papillomavirus 16 E7 peptide pools in patients with cervical neoplasia.
    Lee YS; Lee CW; Song MJ; Ho EM; Kim CJ; Park TC; Kim TG; Park JS
    Acta Obstet Gynecol Scand; 2011 Dec; 90(12):1350-6. PubMed ID: 21916856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide.
    Kadish AS; Timmins P; Wang Y; Ho GY; Burk RD; Ketz J; He W; Romney SL; Johnson A; Angeletti R; Abadi M;
    Cancer Epidemiol Biomarkers Prev; 2002 May; 11(5):483-8. PubMed ID: 12010863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of human papillomavirus (HPV) type 16 E7-expressing lactobacillus-based vaccine for induction of mucosal E7-specific IFNγ-producing cells.
    Komatsu A; Igimi S; Kawana K
    Vaccine; 2018 Jun; 36(24):3423-3426. PubMed ID: 29735324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia.
    Van Doorslaer K; Reimers LL; Studentsov YY; Einstein MH; Burk RD
    Gynecol Oncol; 2010 Feb; 116(2):208-12. PubMed ID: 19555999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia.
    de Gruijl TD; Bontkes HJ; Walboomers JM; Schiller JT; Stukart MJ; Groot BS; Chabaud MM; Remmink AJ; Verheijen RH; Helmerhorst TJ; Meijer CJ; Scheper RJ
    J Natl Cancer Inst; 1997 May; 89(9):630-8. PubMed ID: 9150187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3).
    Kaufmann AM; Nieland JD; Jochmus I; Baur S; Friese K; Gabelsberger J; Gieseking F; Gissmann L; Glasschröder B; Grubert T; Hillemanns P; Höpfl R; Ikenberg H; Schwarz J; Karrasch M; Knoll A; Küppers V; Lechmann M; Lelle RJ; Meissner H; Müller RT; Pawlita M; Petry KU; Pilch H; Walek E; Schneider A
    Int J Cancer; 2007 Dec; 121(12):2794-800. PubMed ID: 17721997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.